SBH
SRPT icon

Segall Bryant & Hamill’s Sarepta Therapeutics SRPT Stock Holding History

Segall Bryant & Hamill’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.64M Buy
+258,154
New +$4.88M 0.06% 326

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Segall Bryant & Hamill's SRPT Position: Q2 2026 in Review

Segall Bryant & Hamill opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 258,154 shares worth $4.64M. The stake represents 0.06% of the portfolio and ranks #326 among its holdings.

323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Segall Bryant & Hamill held 258,154 shares of Sarepta Therapeutics worth $4.64M as of Q2 2026.
  • Sarepta Therapeutics was a new Segall Bryant & Hamill position in Q2 2026.
  • Sarepta Therapeutics made up 0.06% of Segall Bryant & Hamill's portfolio in Q2 2026, its #326 holding.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.